This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.
This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.
Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids. Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK.
Inhaltsangabe
Preface. 1. Mechanism of Action of Anti Inflammatory Drugs: An Overview; J.R. Vane, R.M. Botting. 2. The Structure of Human COX 2 and Selective Inhibitors; M.F. Browner. 3. Differential Inhibition of COX 1 and COX 2 by NSAIDs: A Summary of Results Obtained Using Various Test Systems; M. Pairet, et al. 4. COX 2 in Brain and Retina: Role in Neuronal Survival; N.G. Bazan, et al. 5. COX 2 and Apoptosis: NSAIDs as Effectors of Programmed Cell Death; D.L. Simmons, et al. 6. Inhibition of Intestinal Tumorigenesis via Selective Inhibition of COX 2; R.N. DuBois, et al. 7. Cyclooxygenase Enzymes in Human Vascular Disease; C. Patrono, et al. 8. Gastrointestinal Effects of NSAIDs; C.J. Hawkey. 9. Renal Side Effects of NSAIDs: Role of COX 1 and COX 2; J.C. Frolich, D.O. Stichtenoth. 10. Aspirin Induced Asthma and Cyclooxygenases; R.J. Gryglewski. 11. New Classification of Aspirin like Drugs; H. Fenner. 12. New Highly Selective COX 2 Inhibitors; A.W. Ford Hutchinson. 13. Specific COX 2 Inhibitors: From Bench to Bedside; P. Isakson, et al. 14. Meloxicam: Selective COX 2 Inhibition in Clinical Practice; D.E. Furst. Index.
Preface. 1. Mechanism of Action of Anti Inflammatory Drugs: An Overview; J.R. Vane, R.M. Botting. 2. The Structure of Human COX 2 and Selective Inhibitors; M.F. Browner. 3. Differential Inhibition of COX 1 and COX 2 by NSAIDs: A Summary of Results Obtained Using Various Test Systems; M. Pairet, et al. 4. COX 2 in Brain and Retina: Role in Neuronal Survival; N.G. Bazan, et al. 5. COX 2 and Apoptosis: NSAIDs as Effectors of Programmed Cell Death; D.L. Simmons, et al. 6. Inhibition of Intestinal Tumorigenesis via Selective Inhibition of COX 2; R.N. DuBois, et al. 7. Cyclooxygenase Enzymes in Human Vascular Disease; C. Patrono, et al. 8. Gastrointestinal Effects of NSAIDs; C.J. Hawkey. 9. Renal Side Effects of NSAIDs: Role of COX 1 and COX 2; J.C. Frolich, D.O. Stichtenoth. 10. Aspirin Induced Asthma and Cyclooxygenases; R.J. Gryglewski. 11. New Classification of Aspirin like Drugs; H. Fenner. 12. New Highly Selective COX 2 Inhibitors; A.W. Ford Hutchinson. 13. Specific COX 2 Inhibitors: From Bench to Bedside; P. Isakson, et al. 14. Meloxicam: Selective COX 2 Inhibition in Clinical Practice; D.E. Furst. Index.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Shop der buecher.de GmbH & Co. KG Bürgermeister-Wegele-Str. 12, 86167 Augsburg Amtsgericht Augsburg HRA 13309
